Stocksigma LogoStocksigma Logo

Orchid Pharma Q2 FY27 Monitoring Agency Report Details Full QIP Utilization

CARE Ratings reported that Orchid Pharma Limited has fully utilized its revised net QIP proceeds of ₹394.54 crore as of 30th Sep'26, with zero unutilized

Orchid Pharma Q2 FY27 Monitoring Agency Report Details Full QIP Utilization

Orchid Pharma Ltd · Others (Uncategorized) · 14 Nov 2026, 12:34 am

Orchid Pharma Q2 FY27 Monitoring Agency Report Details Full QIP Utilization CARE Ratings reported that Orchid Pharma Limited has fully utilized its revised net QIP proceeds of ₹394.54 crore as of 30th Sep'26, with zero unutilized funds remaining. Deployments include ₹195.46 crore for debt repayment, ₹135.00 crore for investment in subsidiary Orchid Bio Pharma's Jammu plant, ₹63.72 crore for general corporate purposes, and ₹0.36 crore for the Alathur API unit. Commercial operations at the Jammu manufacturing facility face project implementation delays and are now expected to commence by Feb'27 due to prolonged land acquisition agreements.

Original exchange filing (PDF)

More announcements from Orchid Pharma Ltd

All Orchid Pharma Ltd announcements